Disc Medicine’s Bitopertin Shines, Science Talent Drain Sparks Policy Debate, Vedolizumab Clears UC Without Steroids, Doughnut Model Reveals Critical Links, and more...

(0:10): Disc Medicine's Bitopertin Shines in Phase 3 EPP Trial, Paving Way for FDA Submission

(1:57): US Faces Science Talent Drain Amid Policy Shifts, Immigrant Contributions Highlighted

(3:54): Vedolizumab Achieves Corticosteroid-Free Disease Clearance, Reduces UC Complications in Phase 4 VERDICT Trial

(6:27): Breakthrough Study Links Topology to Critical Phenomena Using Doughnut Model

(8:09): Japan's Leading Biobank Surpasses 250,000 Participants, Expands Global Research Access

To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.

Image credit: Shoreline Media Group

What is Science News Daily?

Welcome to Science News Daily, brought to you by Brief! Our AI selects the latest stories and top headlines and then delivers them to you each day in less than ten minutes (for more details, visit www.brief.news/how-it-works). Tune in to get your daily news on fascinating topics, including physics, biology, chemistry, astronomy, and more. Whether you're a science enthusiast, researcher, or simply curious about the wonders of the natural world, this podcast is your ultimate source for all things science. Tune in daily to stay up-to-date with the latest scientific breakthroughs.

Want to get these updates by email? Subscribe to Brief today https://www.brief.news/